Drug Type Interleukins |
Synonyms VIS171 |
Target |
Mechanism IL-2 replacements(Interleukin-2 replacements), Regulatory T-lymphocytes stimulants |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autoimmune Diseases | Phase 1 | BG | 28 Apr 2022 | |
Autoimmune Diseases | Phase 1 | DE | 28 Apr 2022 | |
Autoimmune Diseases | Phase 1 | MD | 28 Apr 2022 | |
Autoimmune Diseases | Phase 1 | NL | 28 Apr 2022 | |
Autoimmune Diseases | Phase 1 | NZ | 28 Apr 2022 |